Cornerstone BioPharma, Inc. Expands Nationwide Sales Force
Specialty Pharmaceutical Company adds 50 Sales Reps Across the Country
Cary, NC (PRWEB) April 27, 2005
Cornerstone BioPharma, Inc., the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the pain, anti-infective, and respiratory markets, has successfully executed its expansion strategy and recruiting campaign for 50 sales representatives nationwide.
The recruiting efforts were lead by Kevin McAdams, Vice President of Sales. “I am very proud of the efforts put forth by our sales leadership team in securing the incredibly talented individuals that now comprise our new sales force,” said McAdams. “This sales team is undoubtedly one of the most talented and high potential teams I have ever had the privilege of leading. I am confident in their abilities to drive sales and establish Cornerstone BioPharma as a key player in the niche specialty biopharma sector.”
“We are very excited about the hiring of our sales team and we plan to continue our model of expansion as we maintain profitability”, states Craig Collard, CEO.
Cornerstone BioPharma has several product launches planned for 2005 and this sales force will play a critical role in not only the sales of the products, but the education of health care providers, which will ultimately drive the success of these brands. The company is developing a commercially strong product portfolio and an R&D pipeline that will fuel expansion plans.
About Cornerstone Biopharma, Inc.
Cornerstone BioPharma, Inc., located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the pain, anti-infective, and respiratory markets. The privately held company owns the rights to a pain product line, three respiratory product lines, and co-promotes the Suprax® antibiotic. Cornerstone is actively engaged in the licensing of additional prescription products in niche markets through acquisitions and strategic partnerships.
# # #
